With Key US Patent Upheld, Benitec Sets Sights on 'Relaunch,' $8.4M Financing | GenomeWeb

By Doug Macron

Roughly five months after the US Patent and Trademark Office ended a years-long review of Benitec's core patent, the Australian company announced that it is aiming to raise A$8 million ($8.4 million) though a public offering in order to support development of its three drug-development programs.

“This is effectively a relaunch of Benitec following the favorable decision from the US Patent and Trademark Office,” CEO Peter French said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery.